CYP2C19 and myocardial infarction: Regarding cardiovascular diseases, three approaches focused on coronary artery disease, including pharmacogenomic tests for CYP2C19 genotyping, which is implicated in the metabolism of antiplatelet drugs, to establish correct maintenance therapy dosages for patients who had undergone percutaneous coronary intervention for myocardial infarction.